Edward O. List
Leads the mouse studies defining how disrupting growth hormone receptor signaling extends mammalian lifespan
PhD, Ohio University · Research Associate Professor of Biomedical Sciences, Ohio University Heritage College of Osteopathic Medicine · Associate Investigator, Institute for Molecular Medicine and Aging
List is lead author of LIST2026, which showed GH-receptor-antagonist mice lived significantly longer, and co-author of DUR2026, showing adult-onset GH receptor deletion still extends healthy lifespan.
With a PhD from Ohio University, List has spent his career inside the GH/longevity mouse-model pipeline alongside Kopchick and Berryman, co-authoring dozens of core GHRKO papers.
He now runs much of the day-to-day mouse-aging experimental program at the renamed Institute for Molecular Medicine and Aging.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | Growth Hormone Receptor Antagonism Extends Lifespan LIST2026 As lead author, demonstrates transgenic GH receptor antagonist significantly extends median and maximal mouse lifespan. |
| 2026 | A | Midlife Growth Hormone Receptor Ablation Extends Healthy Lifespan and Induces Sex-Specific Hepatic Transcriptional Changes at Single-Cell Resolution DUR2026 Co-authors the finding that adult-onset GH receptor ablation extends healthy lifespan and improves insulin sensitivity. |